These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7879043)

  • 21. Renal target structures in acute allograft rejection.
    Leszczynski D; Laszczynska M; Halttunen J
    Transplant Proc; 1987 Feb; 19(1 Pt 1):378. PubMed ID: 3079159
    [No Abstract]   [Full Text] [Related]  

  • 22. CD4+ T-cell-dependent destruction of MHC class I disparate cardiac allografts.
    Morton AL; Bolton EM; Lawes CM; Porteous C; Bradley JA
    Transplant Proc; 1993 Feb; 25(1 Pt 1):102-3. PubMed ID: 8438240
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of IA antigen+ epidermal cells in rejection of rat skin equivalent grafts.
    Lerner-Tung MB; Hull BE
    Transplantation; 1990 Jun; 49(6):1181-4. PubMed ID: 2163135
    [No Abstract]   [Full Text] [Related]  

  • 24. Posttransplant immune monitoring of anti-HLA antibody.
    Kerman RH; Katz SM; Van Buren CT; Ruth J; McKissick E; Rasmussen S; Kahan BD
    Transplant Proc; 2001; 33(1-2):402. PubMed ID: 11266882
    [No Abstract]   [Full Text] [Related]  

  • 25. Trafficking of donor-derived bone marrow correlates with chimerism and extension of composite allograft survival across MHC barrier.
    Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Yoder B; Siemionow M
    Transplant Proc; 2006 Jun; 38(5):1625-33. PubMed ID: 16797371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
    Friend PJ; Rebello P; Oliveira D; Manna V; Cobbold SP; Hale G; Jamieson NV; Jamieson I; Calne RY; Harris DT
    Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
    [No Abstract]   [Full Text] [Related]  

  • 27. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft.
    Saito S; Fujiwara T; Sakagami K; Kobayashi N; Takaishi Y; Orita K
    Transplant Proc; 1995 Feb; 27(1):518-9. PubMed ID: 7533420
    [No Abstract]   [Full Text] [Related]  

  • 28. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
    Koch U; Choksi S; Marcucci L; Korngold R
    J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperacute rejection from antibody against class II HLA antigens.
    Ghasemian SR; Light JA; Sasaki TA; Barhyte DY
    Clin Transplant; 1998 Dec; 12(6):569-71. PubMed ID: 9850452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kinetics of MHC class I and class II expression in rat renal allografts.
    Heelan BT; Thompson M; McCormack A; Peters AM; Batchelor JR; George AJ
    Transplantation; 1996 Apr; 61(8):1274-7. PubMed ID: 8610432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of major histocompatibility complex matching on renal pathology and OKT4/OKT8 (CD4/CD8) ratio in renal allograft rejection.
    Smart YC; Nanra RS; Hibberd AD; Burton RC
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1627-8. PubMed ID: 3152632
    [No Abstract]   [Full Text] [Related]  

  • 32. Tolerance induction to skin allografts following intrathymic injection with donor-specific splenocytes in major histocompatibility complex class I, class I+MLS, and class I+II disparities.
    Ohzato H; Monaco AP
    Transplant Proc; 1993 Feb; 25(1 Pt 1):297-8. PubMed ID: 8438307
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of CD30 in skin and heart allograft rejection in the mouse.
    Beckmann J; Kurts C; Klebba I; Bayer B; Klempnauer J; Hoffmann MW
    Transplant Proc; 2001; 33(1-2):140-1. PubMed ID: 11266747
    [No Abstract]   [Full Text] [Related]  

  • 34. Prolonged allograft survival in cynomolgus monkeys treated with a monoclonal antibody to the human type I interferon receptor and low doses of cyclosporine.
    Benizri E; Gugenheim J; Lasfar A; Eid P; Blanchard B; Lallemand C; Tovey MG
    J Interferon Cytokine Res; 1998 Apr; 18(4):273-84. PubMed ID: 9568730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kidney-transplant rejection and anti-MICA antibodies.
    Kamoun M; Grossman RA
    N Engl J Med; 2008 Jan; 358(2):195; author reply 196. PubMed ID: 18184968
    [No Abstract]   [Full Text] [Related]  

  • 36. Relationship between cellular and molecular markers of inflammation in human kidney allograft rejection.
    von Willebrand E; Häyry P
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1644-5. PubMed ID: 3079030
    [No Abstract]   [Full Text] [Related]  

  • 37. Class I peptides involved in the indirect pathway of allorecognition.
    Takemoto SK
    Clin Transpl; 1997; ():317-35. PubMed ID: 9919415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in peripheral V beta 11+ T-cell populations are not predictive of allograft rejection in I-E- mice resistant to neonatal tolerance induction.
    Nassiri M; Koh M; Padmanabhan J; Viciana A; Streilein JW; Ruiz P
    Transplant Proc; 1993 Feb; 25(1 Pt 1):368-70. PubMed ID: 8438339
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanisms of human cardiac allograft rejection: absence of co-stimulatory molecules and cell adhesion molecules on major histocompatibility complex class I/II+ human cardiac myocytes does not induce anergy.
    Sundstrom JB; Mayne A; Kanter K; Herskowitz A; Ansari AA
    Transplant Proc; 1995 Feb; 27(1):1310-3. PubMed ID: 7878895
    [No Abstract]   [Full Text] [Related]  

  • 40. Specific inhibition of heart allograft rejection by serum from liver-grafted rats.
    Kamada N; Shinomiya T; Tamaki T
    Transplant Proc; 1987 Feb; 19(1 Pt 1):570-1. PubMed ID: 3274823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.